Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Arbutus Biopharma ( (ABUS) ).
On September 9, 2025, the U.S. District Court for the District of New Jersey issued a claim construction ruling in a lawsuit filed by Arbutus Biopharma and its licensee Genevant Sciences against Pfizer Inc. and BioNTech SE. The lawsuit alleges that Pfizer/BioNTech’s COVID-19 mRNA-based vaccines infringe on several of Arbutus’s patents related to lipid nanoparticle technology. The court’s decision on the construction of disputed patent terms could significantly impact the ongoing litigation and the companies involved, as it addresses key elements of the technology used in the COVID-19 vaccines.
The most recent analyst rating on (ABUS) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Arbutus Biopharma stock, see the ABUS Stock Forecast page.
Spark’s Take on ABUS Stock
According to Spark, TipRanks’ AI Analyst, ABUS is a Neutral.
Arbutus Biopharma’s overall score is driven by significant financial challenges, despite positive corporate events and moderate technical momentum. The company’s negative profitability and cash flow issues weigh heavily, while recent board changes and litigation prospects offer potential upside.
To see Spark’s full report on ABUS stock, click here.
More about Arbutus Biopharma
Arbutus Biopharma Corporation operates in the biopharmaceutical industry, focusing on developing therapies for viral diseases. The company is known for its work on lipid nanoparticle technology, which is used to deliver therapeutic agents, such as mRNA, in a protected manner to enhance their stability and efficacy.
Average Trading Volume: 908,203
Technical Sentiment Signal: Buy
Current Market Cap: $784M
Find detailed analytics on ABUS stock on TipRanks’ Stock Analysis page.